# CJC-1295 (no DAC) + Ipamorelin

> The classic growth-hormone pairing — a GHRH analog (CJC-1295 no-DAC / Mod GRF 1-29) plus a selective secretagogue (Ipamorelin) that act on two different receptors.

- Also known as: CJC-1295/Ipamorelin, Mod GRF 1-29 + Ipamorelin, CJC Ipa
- Class: Growth Hormone
- FDA approved: No
- Canonical page: https://americanpeptide.com/catalog/cjc-1295-ipamorelin

## Overview

A combination of CJC-1295 without DAC (the short-acting GHRH analog also called Mod GRF 1-29) and Ipamorelin, a selective ghrelin-receptor secretagogue. The two are paired because they raise growth hormone through different receptors: CJC-1295 supplies a GHRH signal to the somatotroph, while Ipamorelin acts on the GHS-R to amplify the pulse without the cortisol or prolactin rise of older GHRPs. It is one of the most common GH-secretagogue pairings in the research literature, and a research combination rather than an approved product.

The logic of this pair is that the somatotroph can be pushed from two directions at once. CJC-1295 without DAC provides the GHRH input that tells the pituitary to make and release growth hormone; Ipamorelin acts through the separate ghrelin receptor to sharpen the release pulse. Because the two receptors are distinct, a combined signal is studied for a larger, still-pulsatile GH release than either input gives on its own.

Ipamorelin was chosen for these pairings specifically because it is selective — it drives GH without the appetite, cortisol, and prolactin effects seen with earlier secretagogues such as GHRP-6. The combination is widely referenced but remains a research construct: it is not an FDA-approved drug, and the component peptides are studied individually.

## Mechanism

CJC-1295 (no DAC): GHRH-receptor agonism driving GH synthesis and release. Ipamorelin: GHS-R1a agonism amplifying the GH pulse with high selectivity (minimal ACTH/cortisol/prolactin). Dual-receptor stimulation is studied for a larger, more physiologic pulse than either alone.

## Research areas

Studied in: Growth-hormone secretagogue research, GH pulse amplification, Body-composition models.

Guides on this site:

- [Growth Hormone & Body Composition](https://americanpeptide.com/research-areas/growth-hormone-axis): Secretagogues studied for GH release, IGF-1, and body composition.

## Key research

- Two-receptor design — GHRH (CJC-1295) plus GHS-R (Ipamorelin) stimulation is studied for a larger GH pulse than either pathway alone.
- Selective secretagogue — Ipamorelin amplifies GH with minimal cortisol/prolactin, the reason it is favored over GHRP-6 in these blends.
- Preserved pulsatility — the no-DAC CJC-1295 is short-acting, keeping GH release pulsatile rather than continuously elevated.
- Not FDA-approved — a research combination, not an approved therapeutic.

## Storage, handling & synthesis

**Storage.** Store lyophilized, frozen, and protected from light; after reconstitution keep refrigerated and use within a short window. The blend is only as stable as its least stable component.

**Handling.** Reconstitute gently and treat the certificate as needing per-component data — identity, purity, and content for both the GHRH analog and the secretagogue — rather than one blended figure.

**Synthesis.** A physical mixture, not a single molecule. CJC-1295 (no DAC) and Ipamorelin are synthesized and purified separately, so there is no combined synthesis and no single purity number — a real certificate gives each peptide its own identity and purity assay and states how much of each is present. Co-dissolving two peptides also adds stability questions a single-peptide vial does not have.

## FAQs

### What is CJC-1295 + Ipamorelin?

A pairing of a GHRH analog (CJC-1295 without DAC, aka Mod GRF 1-29) and a selective GH secretagogue (Ipamorelin) that raise growth hormone through two different receptors.

### Why combine a GHRH analog with a GHRP?

They act on separate receptors — GHRH and the ghrelin receptor — so the combined signal is studied for a larger, still-pulsatile GH release than either component alone.

### Why Ipamorelin specifically?

Ipamorelin is the most selective GH secretagogue, raising GH with little effect on cortisol or prolactin, which is why it is paired in these blends rather than GHRP-6.

### Is it approved?

No — it is a research combination and not FDA-approved. This page is a research and educational reference.

---

Source: AmericanPeptide.com — https://americanpeptide.com/catalog/cjc-1295-ipamorelin
Data license: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Attribution: AmericanPeptide.com.
Research reference only — computational and educational content, not medical advice.